LivaNova (NASDAQ:LIVN) Shares Pass Below 50 Day Moving Average – Time to Sell?

LivaNova PLC (NASDAQ:LIVN)’s share price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $48.71 and traded as low as $47.60. LivaNova shares last traded at $47.82, with a volume of 562,307 shares traded.

Analysts Set New Price Targets

Several equities research analysts recently commented on the stock. StockNews.com downgraded shares of LivaNova from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 23rd. Needham & Company LLC restated a “buy” rating and issued a $75.00 target price on shares of LivaNova in a report on Tuesday, January 28th. Mizuho decreased their target price on LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a research report on Thursday, October 31st. Finally, Robert W. Baird upped their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a research report on Thursday, October 31st. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and a consensus price target of $69.17.

LivaNova Stock Performance

The company has a current ratio of 3.37, a quick ratio of 2.87 and a debt-to-equity ratio of 0.46. The firm has a market capitalization of $2.60 billion, a PE ratio of 113.86 and a beta of 1.00. The firm’s fifty day moving average price is $48.71 and its 200 day moving average price is $49.81.

Insider Buying and Selling at LivaNova

In other LivaNova news, Director Francesco Bianchi sold 1,250 shares of LivaNova stock in a transaction that occurred on Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total value of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at $383,546.78. The trade was a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Corporate insiders own 0.27% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently modified their holdings of the business. Point72 Asset Management L.P. boosted its holdings in LivaNova by 62.7% in the third quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after purchasing an additional 806,374 shares in the last quarter. Raymond James Financial Inc. bought a new stake in shares of LivaNova during the 4th quarter worth about $9,645,000. Point72 DIFC Ltd boosted its stake in shares of LivaNova by 75,799.6% during the 3rd quarter. Point72 DIFC Ltd now owns 181,400 shares of the company’s stock worth $9,531,000 after acquiring an additional 181,161 shares in the last quarter. Ruffer LLP acquired a new position in shares of LivaNova during the 4th quarter valued at about $7,982,000. Finally, The Manufacturers Life Insurance Company raised its stake in shares of LivaNova by 286.4% in the 3rd quarter. The Manufacturers Life Insurance Company now owns 207,248 shares of the company’s stock valued at $10,889,000 after acquiring an additional 153,611 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.